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Acetylsalicylic acid differentially 
limits the activation and 
expression of cell death markers 
in human platelets exposed to 
Staphylococcus aureus strains
Adrien Chabert1, Pauline Damien1, Paul O. Verhoeven1,2, Florence Grattard1,2, Philippe 
Berthelot1,2, Fabrice Zeni1,3, Laurence Panicot-Dubois4, Stéphane Robert4, Françoise Dignat-
George4, Marie-Ange Eyraud5, Bruno Pozzetto1,2, Bernard Payrastre6, Fabrice Cognasse1,5, 
Olivier Garraud1,7 & Hind Hamzeh-Cognasse1
Beyond their hemostatic functions, platelets alter their inflammatory response according to 
the bacterial stimulus. Staphylococcus aureus is associated with exacerbated inflammation and 
thrombocytopenia, which is associated with poor prognosis during sepsis. Acetylsalicylic acid and 
statins prevent platelet aggregation and decrease the mortality rate during sepsis. Therefore, we 
assessed whether these two molecules could reduce in vitro platelet activation and the inflammatory 
response to S. aureus. Platelets were exposed to clinical strains of S. aureus in the presence or absence 
of acetylsalicylic acid or fluvastatin. Platelet activation, aggregation, and release of soluble sCD62P, 
sCD40 Ligand, RANTES and GROα were assessed. Platelet cell death was evaluated by analyzing 
the mitochondrial membrane potential, phosphatidylserine exposure, platelet microparticle release 
and caspase-3 activation. All S. aureus strains induced platelet activation but not aggregation and 
decreased the platelet count, the expression of cell death markers and the release of RANTES and 
GROα. Acetylsalicylic acid but not fluvastatin limited platelet activation and inflammatory factor 
release and restored the platelet count by protecting platelets from Staphylococcus-induced expression 
of cell death markers. This study demonstrates that acetylsalicylic acid limits S. aureus-induced effects 
on platelets by reducing cell death, revealing new strategies to reduce the platelet contribution to 
bacteremia-associated inflammation.
Platelets are chiefly known for their hemostatic role, but they have many other functions, particularly in innate 
immunity, host defense against infection and inflammatory processes1–3. Platelets act as sentinels of the vascular 
system due to the variety of receptors they express, such as αIIbβ3, GPIb and Toll-like Receptors (TLRs), which 
enable them to interact with pathogens as well as endothelial and circulating immune cells for various effec-
tor and regulatory functions2, 4. Several studies have demonstrated that platelets can sense pathogen-associated 
molecular patterns (PAMPs) through pathogen recognition receptors (PRRs)1, 5, 6. Moreover, platelets produce 
numerous biological response modifiers (BRMs) such as CD40-ligand (CD40L), a major immunoregulatory mol-
ecule during immune—including inflammatory—responses7, 8.
Staphylococcus aureus (S. aureus) is a pathogen that frequently causes sepsis, which can be particularly 
severe9–11. Indeed, S. aureus bears and releases numerous virulence factors, including enzymes and toxins12, which 
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induce either the formation13 or the degradation of neutrophil extracellular traps (NETs) that can lead to neutro-
phil or macrophage apoptosis14, 15. Exotoxins are particularly important in the interaction between S. aureus and 
platelets. Indeed, α-hemolysin accelerates platelet-neutrophil aggregate formation16 or triggers B-cell lymphoma 
(Bcl-3) synthesis by platelets17. However, there are much conflicting data concerning platelet aggregation upon 
stimulation with S. aureus. Staphylothrombin, for instance, by converting fibrinogen into fibrin promotes the 
aggregation of platelets18. Similarly, Clumping Factor A, associated with specific antibodies, also induces plate-
let aggregation19. In contrast, lipotechoic acid has been shown to inhibit platelet aggregation by preventing the 
mobilization of intracellular calcium20. As very nicely described in the review by Cox et al.2, S. aureus can interact 
with platelets either directly or indirectly through plasma soluble factors, and this diversity of potentially involved 
mechanisms further complicates the elucidation of bacteria-induced platelet aggregation.
Sepsis is frequently accompanied by thrombocytopenia; a previous study showed that the latter follows the 
course of bloodstream infection and parallels adverse outcomes21. These findings collectively suggest that plate-
lets have a crucial role in the pathophysiology of sepsis22, 23. Several mechanisms may cause this reduction in 
platelet count. An infectious environment can induce platelet activation and promote disseminated intravascular 
coagulation, which retains platelets within thrombi formed around the pathogens and thus removes them from 
circulation24. Sepsis-associated thrombocytopenia can also result from increased platelet apoptosis. Indeed, plate-
lets have recently been reported to display features associated with apoptosis pathways such as mitochondrial 
membrane depolarization and caspase cascade activation25, 26. Indeed, increased mitochondrial membrane depo-
larization in platelets has been described as a biomarker of severity in sepsis27, 28. S. aureus has also been shown 
to induce (in vitro) the degradation of the survival protein Bcl-xL, indicating that this bacterium triggers platelet 
apoptosis29.
Molecules such as acetylsalicylic acid (aspirin, ASA) and statins have been used to reduce complications and 
improve survival in patients with a bloodstream infection involving S. aureus30–33, and the antiplatelet effects of 
aspirin reduce severity markers in experimental S. aureus endocarditis34. However, recent studies have also shown 
that aspirin induces platelet apoptosis35 and reduces the platelet life span36; thus, the effects of this drug may be 
complex in sepsis patients37. Overall, it appears particularly important to counteract the occurrence of thrombo-
cytopenia during sepsis and to identify the effects of antiplatelet molecules38. Elucidating the mechanisms that 
are collectively responsible for platelet impairment in sepsis, using ASA as a tool, can help determine previously 
unknown causes and may be translated into clinical solutions.
Results
S. aureus strains differentially alter the platelet count. The effects of several live S. aureus clinical 
strains isolated from bacteremia on normal platelets were evaluated under ex vivo conditions to assess the resid-
ual post-exposure counts of viable normal platelets. These strains were compared to the effects of a non-clinical, 
food-derived strain, Staphylococcus condimenti, which is poorly associated with human pathologies39, and a ref-
erence methicillin-resistant strain of S. aureus, ATCC43866. We observed that S. condimenti did not affect the 
platelet counts compared with the controls (platelets not exposed to S. aureus strains but to a vehicle control, 
Tyrode’s buffer) (146.3 ± 15.6 × 106 Pl/ml vs. 163.2 ± 5.3 × 106 Pl/ml, respectively, p > 0.05). In contrast, all clinical 
S. aureus strains isolated from bacteremia (SaB) drastically and significantly reduced platelet counts (p < 0.001) 
comparably to the effects of Thrombin receptor activator peptide (TRAP)-stimulation (Fig. 1). Indeed, from an 
initial count of 163.2 ± 5.3 × 106 Pl/ml, the platelet counts decreased to a range from 14.2 ± 4.9 × 106 Pl/ml to 
Figure 1. Platelet counts following exposure to Staphylococcus strains. After a 30-min exposure to the 
staphylococcal strains, TRAP (as a positive control) or Tyrode’s buffer (as a negative control, NS), platelet 
counts were assessed with a MS4s Hematology analyzer [Tyrode (n = 42), TRAP (n = 40) or Staphylococcus 
strains: clinical strains (SaB), S. condimenti (Sc) or S. aureus ATCC 43866 (ATCC43866)] (n = 12). The data 
(mean ± SEM) are expressed as the platelet count × 106/ml ****p < 0.0001 (one-way ANOVA with repeated 
measures and the Bonferroni post hoc test; stimulated vs. unstimulated, NS).
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25.2 ± 7.3 × 106 Pl/ml after SaB31 and SaB19 stimulation, respectively, and reached 8.77 ± 0.8 × 106 Pl/ml after 
stimulation with TRAP.
The reduction in platelet counts appeared to be related to an alteration in platelet morphology that prevented 
their automatic counting according to their size/structure by the hematological analyzer. Indeed, fluorescence 
microscopy experiments showed that 48% of unstimulated platelets maintained their usual size (less than 4 µm) 
and discoid shape (Supplemental Fig. 1a), and 31% of TRAP-stimulated platelets retained their size; the remain-
der spread and aggregated (Supplemental Fig. 1b), and only 21% of platelets exposed to the SaB24 bacteremia 
strain maintained a size less than 4 µm (Supplemental Fig. 1c). Moreover, the SaB24 strain promoted a dramatic 
change in morphology involving the spreading and emission of pseudopods.
S. aureus strains promote platelet activation but do not lead to platelet aggregation. We eval-
uated the impact of S. aureus stimulation on platelets by assessing the expression of the platelet activation markers 
CD62P and CD63. TRAP, which was used as a positive control, induced strong and significant expression of 
CD62P (79.3 ± 2.3%) (Fig. 2a/Supplemental Fig. 2a) and CD63 (40.4 ± 2.6%) (Fig. 2b/Supplemental Fig. 2b). 
The non-pathogenic staphylococcal strain S. condimenti promoted the modest expression of CD62P on plate-
lets (37.2 ± 5.4% vs. 15.6 ± 2.2%, p < 0.001) (Fig. 2a/Supplemental Fig. 2a) and no significant increase in CD63 
(10.9 ± 2.6% vs. 3.4 ± 0.6%, p > 0.05) (Fig. 2b/Supplemental Fig. 2b). Clinical and reference S. aureus strains 
induced significant expression of both CD62P and CD63 (Fig. 2a and b/Supplemental Fig. 2a and b, respectively).
S. condimenti failed to induce any significant release of RANTES, GROα, sCD62P, thromboxane B2 or 
sCD40L by platelets (11816 ± 1276 pg/ml, 381 ± 62 pg/ml, 41 ± 5 ng/ml, 19.8 ± 3.5 ng/ml and 690 ± 303 pg/ml, 
respectively) compared with unexposed platelets (6753 ± 597 pg/ml, 836 ± 311 pg/ml, 44 ± 5 ng/ml, 36.7 ± 7.2 ng/
ml and 632 ± 195 pg/ml for RANTES, GRO-α, sCD62P, thromboxane B2 and sCD40L, respectively, Fig. 3).
Every S. aureus strain exposed to platelets resulted in the release of significant amounts of RANTES, with lev-
els ranging between 16222 ± 3131 pg/ml and 21023 ± 2142 pg/ml, for the SaB31 and ATCC43866 strains, respec-
tively; this secretion is copious but was less than that induced by platelet exposure to TRAP (36688 ± 1022 pg/ml) 
(Fig. 3a). Platelets exposed to ATCC43866, SaB32 and SaB24 strains released significantly elevated amounts of 
GRO-α (2580 ± 296 pg/ml, 3112 ± 323 pg/ml and 3477 ± 348 pg/ml, respectively) (Fig. 3b). However, these levels 
were less than those induced by TRAP (4642 ± 1470 pg/ml vs. 836 ± 311 pg/ml in unexposed platelets, p < 0.0001, 
Fig. 3b). The SaB19 and SaB31 strains induced no significant release of GRO-α by platelets (Fig. 3b). All S. aureus 
Figure 2. Platelet activation level after Staphylococcus aureus stimulation. Expression levels of the CD62P (a) 
and CD63 (b) activation markers on platelets were analyzed after stimulation for 30 min with staphylococcal 
strains [clinical strains (SaB), S. condimenti (Sc) or S. aureus ATCC 43866 (ATCC43866)], TRAP (as a positive 
control) or Tyrode’s buffer (as a negative control, NS). Membrane expression of CD62P and CD63 after gating 
on CD41 was assessed by flow cytometry, and data (mean ± SEM; n = 10 experiments) are expressed as the 
percentage of positive cells. *p < 0.05; **p < 0.01***p < 0.001; ****p < 0.0001 (one-way ANOVA with 
repeated measures and the Bonferroni post hoc test; stimulated vs. unstimulated, NS).
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strains, excluding SaB19 and SaB31, the effects of which were not statistically significant, induced a significant 
increase in specific cytokines, in contrast to the non-pathogenic strain S. condimenti.
Only SaB24 stimulation resulted in an increased production of sCD40L, although it was non-significant 
(4642 ± 1470 pg/ml, and 2410 ± 842 pg/ml, respectively, vs. 632 ± 195 pg/ml; (Fig. 3c). Neither the S. aureus 
Figure 3. Platelet cytokine release in response to S. aureus stimulation. RANTES (a) GROα (b) sCD40L 
(c) sCD62P (d) and thromboxane B2 (e) release by platelets were analyzed after stimulation for 30 min with 
staphylococcal strains [clinical strains (SaB), S. condimenti (Sc) or S. aureus ATCC 43866 (ATCC43866)], TRAP 
(as a positive control) or Tyrode’s buffer (as a negative control, NS). Immunomodulatory factor levels were 
assessed by ELISA or Luminex® assays, and data (mean ± SEM; n = 10 experiments) are expressed as pg/ml or 
ng/ml (sCD62P and thromboxane B2). *p < 0.05; **p < 0.01***p < 0.001; ****p < 0.0001 (one-way ANOVA 
with repeated measures and the Bonferroni post hoc test; stimulated vs. unstimulated, NS). The dotted line 
represents the unstimulated value.
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strains nor the non-pathogenic strain S. condimenti altered the baseline production of sCD62p, in contrast to 
TRAP (103 ± 17 ng/ml compared with the unstimulated value of 44 ± 5 ng/ml, p < 0.001, Fig. 3d). The same 
results were observed for thromboxane B2 release (167.6 ± 15.9 ng/ml for TRAP compared with the unstimu-
lated value of 36.7 ± 7.2 ng/ml, p < 0.001, Fig. 3e). Overall, similar to the non-pathogenic S. condimenti strain, 
all S. aureus strains failed to induce the release of thromboxane B2, sCD40L and sCD62P by platelets, except the 
SAB24 strain, which induced an increase in sCD40L release, although this increase was not significant. However, 
the strains succeeded in differentially mobilizing platelet stores, as demonstrated by the significant release in 
either RANTES or GRO-α. Thus, S. aureus strains altered the secretion profile of exposed platelets with different 
patterns rather than a unique pattern.
We next assessed whether the aggregation capacity of platelets was altered in the presence of clinical and refer-
ence S. aureus strains (because platelets tend to clump around bacteria to seclude them and limit infection40). We 
did not observe any platelet aggregation during a 30-min stimulation, a time frame that allowed aggregation in 
response to TRAP or to the weaker agonist ADP, with any staphylococcal strains (Fig. 4). Five of 35 platelet-rich 
plasma (PRP) samples resulted in partial aggregation (Supplemental Fig. 3), suggesting a modest donor depend-
ency, and they were not included in the whole aggregation dataset.
S. aureus strains promote platelet cell death. The apparent effect of clinical S. aureus strains on viable 
platelet counts, platelet activation, changes in morphology and the release of inflammatory factors suggested a 
robust upheaval in platelet physiology and led us to question whether exposure to bacteria in vitro could trigger 
Figure 4. Platelet aggregation after S. aureus exposure. Aggregation was assessed using a thrombo-
aggregometer after exposure (a/c) to Tyrode’s buffer (NS), S. condimenti (Sc) and S. aureus ATCC43866 (ATCC 
43866) or (b/d) to clinical strains (SaB). TRAP (a/b) or ADP (c/d) was added as a positive control at the end of 
the stimulation (one representative experiment is presented; n = 5–10 experiments). The aggregation baseline 
was approximately 20% due to the added volume.
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a platelet cell death signal. To achieve this goal, we assessed membrane depolarization in platelet mitochondria 
using DIOC6(3) staining after exposure to various staphylococcal strains.
There was a significant decrease in DIOC6(3) mean fluorescence intensity (MFI) in platelets following stim-
ulation with a TRAP agonist (4239 ± 447 arbitrary unit, AU) or the apoptosis inducer A23187 (2229 ± 151 AU, 
p < 0.0001) compared with the control (12019 ± 571 AU, p < 0.0001). Exposure of the platelets to all S. aureus 
strains, except S. condimenti, led to a significant decrease in the DIOC6(3) MFI (3704 ± 488 AU for SaB19, 
3153 ± 601 AU for SaB24, 5223 ± 721 AU for SaB31, 4028 ± 700 AU for SaB32 and 3163 ± 688 AU for ATCC 
43866 p < 0.0001; 10614 ± 1167 AU, for S. condimenti, p > 0.05) (Fig. 5a).
Next, we examined platelet phosphatidylserine (PS) exposure, which corresponds to a later stage of platelet 
cell death, using Annexin V binding. The TRAP agonist and apoptosis inducer A23187 promoted significant 
platelet expression of Annexin V (33.7 ± 1.3%, p < 0.0001; 31.1 ± 2%, p < 0.0001, respectively) compared with 
unstimulated platelets (16.3 ± 0.8%). Platelet Annexin V expression increased after exposure to all staphylococcal 
strains, except S. condimenti (28.4 ± 1.4% for SaB19, p < 0.005; 27.3 ± 0.7% for SaB24, p < 0.01; 31.4 ± 3.4% for 
SaB31, p < 0.005; 36.5 ± 2.3% for SaB32, p < 0.0001; 29.8 ± 2.7% for ATCC 43866, p < 0.01), compared with the 
control (16.3 ± 0.8%), indicating increased PS exposure after S. aureus treatment (Fig. 5b).
We also measured platelet microparticle (PMP) formation. Both TRAP and A23187 induced significant 
release of PMPs (3194 ± 595 PMPs/µl, p < 0.01; 3075 ± 500 PMPs/µl, p < 0.01) compared with unstimulated 
platelets (1576 ± 118 PMPs/µl). However, despite a non-significant increase in PMP formation in the pres-
ence of clinical strains, no difference was observed for S. condimenti (1405 ± 287 PMPs/µl) and ATCC 43866 
(1518 ± 243 PMPs/µl), but every other strain exhibited increased PMP formation (2248 ± 283 PMPs/µl for SaB19; 
2400 ± 303 PMPs/µl for SaB24; 2182 ± 326 PMPs/µl for SaB31; 2389 ± 243 PMPs/µl for SaB32), in contrast to 
the unstimulated platelets (1576 ± 118 PMPs/µl) (Fig. 5c). Similarly, the level of active caspase-3 increased only 
upon TRAP stimulation (3.0 ± 0.7-fold increase vs unstimulated control, NS, p < 0.001, Fig. 5d). Although not 
Figure 5. S. aureus-induced platelet cell death. (a) MFI of platelet-bound DIOC6(3) (b) Annexin V binding (c) 
PMP concentration or (d) fold increase in active caspase-3 expression were analyzed by flow cytometry after 
30 min of exposure to Tyrode’s buffer (NS), TRAP, staphylococcal strains [clinical strains (SaB), S. condimenti 
(Sc) or S. aureus ATCC 43866 (ATCC43866)] or the A23187 apoptosis inducer as a positive control. The data 
(mean ± SEM; n = 8 experiments) are expressed as the AU (a), % expression (b) or fold increase compared with 
NS (d). The PMP concentration (mean ± SEM; n = 6–27 experiments) (c) is expressed as microparticles/µl. 
*p < 0.05, **p < 0.01, ****p < 0.0001 (one-way ANOVA with repeated measures and the Bonferroni post hoc 
test; stimulated vs. unstimulated, NS).
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significant, the ATCC43866 S. aureus strain induced an increase in activated caspase-3 expression comparable to 
that triggered by the A23187 apoptosis inducer (1.7 ± 0.1-fold increase for ATCC43866 vs 1.9 ± 0.3-fold increase 
for A23187 stimulation).
ASA, in contrast to fluvastatin, reduces the S. aureus-induced reduction in platelet counts. We 
next examined whether antiplatelet drugs can interfere with the effects of S. aureus strains on platelets. We selected 
two distinct antiplatelet drugs, ASA and fluvastatin, which target cyclooxygenase and 3-hydroxy-3-methylglutaryl 
coenzyme A reductase, respectively38, 41.
First, we assessed the ability of antiplatelet molecules to prevent the platelet count decrease after exposure to S. 
aureus strains. Notably, when there was no reduction in platelet counts (such as in the presence of S. condimenti), 
and neither ASA nor fluvastatin had any detectable effect. In contrast, ASA and fluvastatin did not prevent the 
platelet count reduction induced by platelet exposure to TRAP. Furthermore, fluvastatin did not reverse the plate-
let count reduction observed after the platelets were exposed to any of the clinical or reference strains of S. aureus. 
In sharp contrast, ASA partially prevented the platelet count reduction caused by platelet exposure to the SaB31, 
SaB32 and ATCC 43866 strains compared with the control vehicle (water) (71 ± 14.7 vs. 14.2 ± 4.9 × 106 Pl/
ml, p < 0.0001; 58.7 ± 13.6 vs. 16.2 ± 4.2 × 106 Pl/ml, p < 0.01; 63.5 ± 9.6 vs. 22.2 ± 3.3 × 106 Pl/ml, p < 0.01, 
respectively) (Fig. 6). ASA was less effective when platelets were exposed to SaB19 or SaB24 (49.7 ± 10.4 vs. 
25.2 ± 7.3 × 106 Pl/ml, and 40.5 ± 6.7 vs. 17.3 ± 4.7 × 106 Pl/ml, p > 0.05, respectively) (Fig. 6).
ASA limits S. aureus-induced platelet activation. Next, we examined whether ASA affects the platelet 
activation phenotype following platelet exposure to bacteria. We observed a significant decrease in CD62P or 
CD63 expression by platelets following ASA treatment after exposure to any of the Staphylococcus strains—the 
clinical ones as well as S. condimenti (Fig. 7a/b). Indeed, CD62P + platelet expression was reduced to 22.2 ± 3.8%, 
18.4 ± 0.9%, 18.6 ± 2.0%, 10.3 ± 1.9%, 23.8 ± 3.3% and 27.6 ± 3.7% following exposure to S. condimenti, SaB19, 
SaB24, SaB31, SaB32 and ATCC 43866, respectively, in the presence of ASA, compared with 37.2 ± 5.4%, 
54.3 ± 4.2%, 61.3 ± 3.7%, 55.8 ± 4.0%, 70.8 ± 3.4% and 65.0 ± 5.0% for the same strains, respectively, in the 
absence of ASA (p < 0.0001).
A similar phenomenon was observed for CD63 expression, which was significantly reduced in the presence 
of ASA, regardless of the S. aureus strain used. For example, the maximal CD63 expression by platelets upon S. 
aureus SaB32 exposure reached 28.2 ± 5.1% but was reduced to 5.6 ± 1.2% in the presence of ASA (p < 0.0001). 
Notably, fluvastatin did not reverse any of the S. aureus-induced activation signals assessed under these condi-
tions (Fig. 7a/b).
Thereafter, we assessed whether ASA and fluvastatin could reduce the release of immunomodulatory factor 
by platelets exposed to the various S. aureus strains. Again, fluvastatin had no noticeable effects and did not pre-
vent platelet secretion following exposure to clinical S. aureus strains (Fig. 7c–d). In contrast, ASA significantly 
reduced the secretion of RANTES or GROα, although for a limited number of S. aureus strains (Fig. 7c/d). ASA 
reduced the secretion of RANTES when platelets were exposed to SaB31 or ATCC43866 (8038 ± 1770 pg/ml 
and 14617 ± 1315 pg/ml, respectively, vs. 16222 ± 3101 pg/ml and 21023 ± 2142 pg/ml; p < 0.05). ASA limited the 
secretion of GROα by platelets when they were exposed to SAB24 and SAB32 but not to others (1920 ± 484 pg/
ml and 1216 ± 305 pg/ml, respectively, vs. 3477 ± 348 pg/ml; p < 0.01 or 3112 ± 323 pg/ml p < 0.001) (Fig. 7d). A 
moderate decrease in the secretion of GROα by platelets exposed to SaB19, SaB31 and ATCC43866 was observed 
but remained modest and non-significant (Fig. 7d).
We next investigated whether the modest aggregation observed for the very few PRP samples (n = 5) exposed 
to staphylococcal stimuli was altered by either ASA or fluvastatin. Indeed, we observed that ASA but not fluvas-
tatin efficiently protected platelets against S. aureus-induced aggregation (Supplemental Fig. 3). These data are 
Figure 6. Effect of ASA and fluvastatin on the S. aureus-induced reduction in platelet counts. Platelet counts 
after a 30-min exposure to staphylococcal strains [clinical strains (SaB), S. condimenti (Sc) or S. aureus 
ATCC 43866 (ATCC43866)], TRAP (as a positive control) or Tyrode’s buffer (as a negative control, NS), 
ASA, fluvastatin or water (as a control vehicle) [control vehicle (n = 42), TRAP (n = 40) or Staphylococcus 
strains (n = 10)]. The data (mean ± SEM) are expressed as the platelet count × 106/ml. *p < 0.05,**p < 0.01; 
****p < 0.0001 (two-way ANOVA with repeated measures and the Bonferroni post hoc test; ASA or fluvastatin 
vs. control vehicle).
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limited in that the results were not universal among our platelet samples, but they indicate the potential benefit of 
ASA at least for platelets that aggregate in response to S. aureus.
ASA efficiently protects platelets against S. aureus-induced cell death. We then investigated 
whether ASA affects the reduction in S. aureus-induced platelet counts, i.e., induced cell death. As expected, since 
fluvastatin had little effect on the reduction in platelet counts in the presence of bacteria, this drug did not prevent 
membrane depolarization in platelet mitochondria induced by S. aureus (Fig. 8a). In contrast, ASA had a strong—
almost complete—protective effect against S. aureus-induced platelet cell death. Indeed, the DIOC6(3) MFI was 
reduced to values between 3153 ± 601 and 5253 ± 721 AU upon bacterial exposure in the absence of treatment. 
Figure 7. Effect of ASA and fluvastatin on S. aureus-induced platelet activation. Expression levels of the CD62P 
(a) and CD63 (b) activation markers and immunomodulatory factor release of RANTES (c) and GROα (d) 
by platelets were analyzed after stimulation for 30 min with staphylococcal strains [clinical strains (SaB), S. 
condimenti (Sc) or S. aureus ATCC 43866 (ATCC43866)] with TRAP (as a positive control) or Tyrode’s buffer 
(as a negative control, NS), ASA, fluvastatin or water (as a control vehicle). Membrane expression of CD62P 
and CD63 after gating on CD41 was assessed by flow cytometry, and data (mean ± SEM; n = 10 experiments) 
are expressed as the percentage of positive cells. Immunomodulatory factor levels were assessed by ELISA or 
Luminex® assays, and data (mean ± SEM; n = 14–30 experiments)) are expressed as pg/ml or ng/ml (sCD62P). 
*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001 (two-way ANOVA with repeated measures and the 
Bonferroni post hoc test; ASA or fluvastatin vs. control vehicle).
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However, the DIOC6(3) MFI was significantly restored to levels between 8466 ± 426 and 9390 ± 965 AU in the 
presence of ASA (p < 0.0001 for SaB19, SaB24 and ATCC43866 strains; p < 0.001 for SaB32 strain and p < 0.01 
for SaB31 strain), which were comparable to that of unstimulated platelets (12019 ± 571 AU).
Concerning platelet PS exposure, which is usually observed during the final step of apoptosis and during 
necrosis42, ASA reduced platelet Annexin V expression induced by all S. aureus strains but showed no effect on 
platelets exposed to S. condimenti since this strain did not induce significant PS exposure. Indeed, the percentage 
of cells with CD41/Annexin V decreased from values between 27.4 ± 0.7% and 36.6 ± 2.3% after staphylococcal 
exposure alone to 16.7 ± 1.4% and 19.1 ± 0.8% in the presence of ASA (p < 0.0001 for SaB32, p < 0.05 for SaB19, 
Figure 8. Effect of ASA and fluvastatin on S. aureus-induced platelet cell death. (a) The MFI of platelet-bound 
DIOC6(3) (b) Annexin V binding (c) PMP concentration or (d) fold increase in active caspase-3 expression 
were analyzed by flow cytometry after 30 min of exposure to Tyrode’s buffer (as a negative control, NS), TRAP, 
staphylococcal strains [clinical strains (SaB), S. condimenti (Sc) or S. aureus ATCC 43866 (ATCC43866)] or 
the A23187 apoptosis inducer (as a positive control), with ASA, fluvastatin or water (as a control vehicle). 
(a) The data (mean ± SEM; n = 8) are expressed as AU. (b) The data (mean ± SEM; n = 8) are expressed as 
the % expression (c) The data (mean ± SEM; n = 9–27 experiments) are expressed as microparticles/µl. The 
data (mean ± SEM; n = 6–15 experiments) are expressed as the fold increase in active caspase-3 expression. 
**p < 0.01; ***p < 0.001, ****p < 0.0001 (two-way ANOVA with repeated measures and the Bonferroni post 
hoc test; ASA or fluvastatin vs. control vehicle).
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SaB24, SaB31 and ATCC43866 strains, Fig. 8b). These levels were comparable to those of unstimulated platelets 
(16.57 ± 0.9%), indicating a strong protective effect of ASA on platelet cell death induced by S. aureus strains.
Finally, no difference was observed for each Staphylococcus strain in the presence of ASA with respect to the 
release of PMPs (Fig. 8c) or the expression of active caspase-3 (Fig. 8d). The presence of fluvastatin had no effect 
either on the formation of PMPs or on the expression of active caspase-3.
Discussion
We found a pathogenic effect of clinical and reference strains of S. aureus on platelets from healthy donors, while 
S. condimenti, a food-derived strain associated only once with bloodstream infection39, had a moderate effect. 
Indeed, S. aureus is predominantly reported during bacteremia and causes a variety of infections that frequently 
result in death9, 10. We observed that freshly obtained platelets exposed to clinical and reference S. aureus strains 
for 30 min showed an altered morphology and expressed activation markers, such as CD62P and CD63, with a 
strong effect on CD62P, regardless of the strains used. Genotyping of the strains revealed that while some genes 
associated with virulence were present in all strains, for instance ClfA/B, FnbA/B, LukS/F, Hla, others, such as Cna 
EntA or SasG, were expressed only by some strains (Supplemental Table 1). However, no strain appeared to have 
a more pronounced effect than another on the platelet response. Thus, the use of isogenic mutants to examine 
the participation of each virulence factor in the induction of the platelet response would be helpful. In addition, 
none of the tested strains induced platelet aggregation, except for 5 donors. Indeed, strain SAB24 induced aggre-
gation in 2 donors, as did strain SAB32, whereas strain ATCC43866 induced the aggregation of only one donor. 
Therefore, the host specificity of the response should also be taken into account.
Concerning immunomodulatory factors, every strain of S. aureus but not S. condimenti induced significant 
release of RANTES and of GROα for some strains. Thus, platelets exposed to S. aureus strains could actively 
contribute to the elevated plasma levels of RANTES and GROα that have been described during the course of S. 
aureus bloodstream infection and sepsis43, 44. GROα levels have also been shown to correlate with several clini-
cal scores (Pediatric Risk of Mortality, Sepsis-related Organ Failure Assessment and Disseminated Intravascular 
Coagulation scores)45. Regarding RANTES, murine models of lipopolysaccharide-induced acute lung injury46 
and of polymicrobial sepsis47 revealed the involvement of platelet-derived RANTES in lung damage, underscor-
ing the contribution of this chemokine and the potential implication of platelets in sepsis-associated complica-
tions. Interestingly, we observed in our study that in the presence of ASA, the expression of activation makers on 
platelets was restored to unstimulated levels, and the release of RANTES and GROα was reduced.
Given that we used a multiplicity of infection (MOI) of 0.1 and that the bacterial suspension was washed 
to remove soluble bacterial products, it was likely that platelet activation was propagated by thromboxane B2 
released by platelets since ASA could reduce this activation. However, we did not observe any release of this factor 
in the presence of S. aureus strains. This finding suggests that under the present conditions, ASA either might 
reduce prostaglandin E2 rather than thromboxane B2, or exert Cox-independent effects, as observed for NF-κB, 
although described for high doses of ASA48.
In addition to their well described PS-related procoagulant activity49, platelet microparticles have been shown 
to be predominantly found in the circulation during sepsis50, to have an inflammatory role in rheumatoid arthri-
tis51 and also to have immunosuppressive properties52, 53. Therefore, their contribution to the inflammatory/
immunosuppressive component of sepsis should not be underestimated. Although not significant under our 
conditions, probably because of a requirement for a longer contact duration, the increased release of platelet 
microparticles following S. aureus exposure could synergize with the release of RANTES and GROα to promote 
an immunomodulatory environment, contributing to sepsis pathophysiology.
These data, on the one hand, confirm that platelet secretion triggered by exposure to infectious pathogens is 
not “all or none,” as diverse S. aureus strains elicited different secretion profiles, and on the other hand, show that 
platelet inhibitors such as ASA also have differential effects on these secretion patterns. These results support 
previous studies showing that human platelets have the capacity to differentially detect external signals and adapt 
their inflammatory responses54–56. In addition to their hemostatic role, platelets have an important inflammatory 
function. In fact, platelets are sentinels in the circulation due to the number of immunoreceptors expressed on 
their surface (FcγRII, Toll-like receptors, complement receptor or αIIbβ3), which detect pathogens and par-
ticipate in inflammation. Moreover, platelets interact with macrophages and neutrophils, leading to pathogen 
phagocytosis and NET formation4, 57. Although many studies have investigated the effects of bacteria on platelet 
hemostatic responses58–60, few studies have focused on their immunoregulatory role61, 62, although this could be a 
potential target to reduce bacterial sepsis38.
Previous studies have reported platelet apoptosis in response to Escherichia coli or peptidoglycan, a compo-
nent of S. aureus cell walls29, 63. In this study, we showed that in contrast to the food-derived S. condimenti strain, 
exposure to clinical or reference strains of S. aureus promoted PS exposure and mitochondrial membrane depo-
larization, which are features of both apoptosis and necrosis in platelets. However, the slight increase in both PMP 
release and active caspase-3 expression, although not significant, suggests the initiation of an apoptotic process 
that might require a longer exposure to S. aureus strains but does not exclude the occurrence of a necrotic process. 
Indeed, it has previously been elegantly shown that mitochondrial membrane depolarization and PS exposure 
were induced either by an apoptosis inducer or by the thrombin/collagen combination that induces necrotic 
platelets42. Thus, the use of a cell death marker, such as GSAO, associated with the expression of CD62P would 
help discriminate between apoptosis and necrosis under our conditions.
Conversely, we did not observe platelet aggregation during staphylococcal strain exposure, indicating that 
platelets have the capacity to distinguish inflammatory from aggregation responses depending on the bacterial 
types59, 64 or concentration65. However, there remains some controversy over the induction of platelet aggrega-
tion by S. aureus or its compounds. Several very nice studies report that S. aureus promotes platelet aggregation 
through Clumping Factor A60, which binds fibrinogen and IgG and activates the platelet GPIIb/IIIa and FCγRIIa 
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receptors through the thromboxane A2 and ADP pathways66. However, platelets also harbor innate immunity 
receptors, such as TLR2 and TLR4, which, when triggered, may66, 67 or may not20, 68 lead to platelet aggregation. 
These phenomena raise questions regarding the platelet response according to the receptor engaged by bacteria 
and, more likely, the synthesis of the signalling pathways within platelets when several receptors are simultane-
ously engaged due to the multiplicity of potentially involved ligand/receptor pairs. Moreover, it is also important 
to consider the variability in virulence factor expression by bacterial strains because some, such as staphylothrom-
bin, may promote aggregation18, while others, such as alpha-hemolysin, may inhibit it, as elegantly demonstrated 
by Powers et al.69. Finally, parameters of the host might also intervene, as observed in our study showing that 
under the same stimulation conditions, platelets from 5 of 35 donors aggregated in response to 3 of our strains.
We also evaluated the ability of molecules with marked antiplatelet activity, such as ASA and fluvastatin, to 
reduce platelet activation and secretion of inflammatory factors and potentially also limit platelet cell death30–33, 70 
and PMP release71. Regarding statins, we observed that fluvastatin had no inhibitory effect on platelets after any 
in vitro S. aureus strain exposure, whereas recent studies have shown an inhibition of platelet hemostatic function 
with fluvastatin via downregulation of thromboxane A2 platelet synthesis72–74. Statins such as fluvastatin, but 
particularly simvastatin, have shown a protective effect against abdominal sepsis predominantly by improving 
endothelial function and decreasing pulmonary inflammation75. Additional studies are needed to understand 
the effects of statins on platelet function during sepsis. According to Merx et al., enhanced nitric oxide and cyclic 
GMP formation could play a role in the antiplatelet activity of simvastatin after sepsis induction70.
In contrast, in the present study, the administration of ASA (500 µM) was shown to modify platelet functions 
with a protective effect on the decrease in platelet count, a significant decrease in the activation phenotype and 
complete protection against platelet-induced cell death after exposure to clinical or reference S. aureus strains. 
Platelet cell death, whose mechanism could be related to apoptosis or necrosis42, would thus be implicated in 
the decreased platelet counts that occur during S. aureus bacteremia. Conversely, it has been shown that ASA 
(used at 5 mM, 10 times more concentrated than in our study) induced platelet apoptosis via the upregulation of 
pro-apoptotic proteins or mitochondrial pathways35, 36.
Platelet cell death induced by S. aureus strains can promote deleterious responses during sepsis via different 
mechanisms: (1) thrombocytopenia, which represents an important complication of sepsis; (2) immunomod-
ulatory factors present in platelets or in microparticles, which are secreted and participate in the inflammatory 
phase of sepsis; and (3) the reduction in ‘vital NETosis’, in which platelet-induced NETs help capture and clear 
bacteria76. However, the detrimental role of NETs should not be underestimated because NETs have been shown 
to enhance thrombosis77, although new evidence tends to distinguish the effects of intact NETs from those of 
DNA and histones in the induction of coagulation78.
Due to their dual hemostatic and inflammatory roles, platelets could be targeted by ASA to limit the harmful 
effects of S. aureus on platelets and improve clinical outcomes in S. aureus-induced bacteremia79, 80. However, 
in the lipopolysaccharide-induced sepsis model in mice, ASA pretreatment reduced the survival rate by inhib-
iting the protective effect of platelets on macrophage-dependent inflammation81. Thus, more studies with more 
complex models are needed to better understand the inflammatory role of platelets during sepsis. Drugs such as 
ASA that have direct and indirect effects on platelets may be promising treatments to limit the severity of clinical 
sepsis; however, further studies are needed.
Methods
Ethical considerations. In accordance with the French Public Health Code (article L. 1223-3) and the pro-
cedures of the French Blood Bank ethical board (Etablissement Français du Sang – EFS), volunteer blood donors 
signed the donation form indicating that they did not preclude the use of their donation for non-therapeutic 
purposes. Thus, in accordance with the Declaration of Helsinki, informed and written consent has been obtained 
from all the healthy donors who participated in this study for the sampling of blood for scientific purposes. 
Analyses have been performed anonymously, in accordance with the relevant guidelines and regulations of the 
Lyon University (UJM, Faculty of Medicine, Saint-Etienne, France).
Preparation of platelets and Staphylococcus strains. PRP was prepared as previously described82. 
Briefly, peripheral blood was collected from healthy donors in endotoxin-free tubes with 3.2% sodium citrate 
(Becton Dickinson, San Jose, CA, USA) and centrifuged at 150 × g for 10 min at 22 °C. There was no detectable 
contamination of platelets by residual mononuclear cells as assessed by flow cytometry (CD3-T cells, CD19-B 
cells, or CD14-monocytes) (Supplemental Fig. 4). Platelets were counted in freshly prepared PRP with a MS4s 
Hematology analyzer (Melet Schloesing, Osny, France), and cell suspensions were adjusted to 3 × 108 Pl/ml with 
Tyrode’s buffer (Sigma-Aldrich, Saint Quentin-Fallavier, France) containing 0.04 U/ml of apyrase (Sigma-Aldrich, 
Saint Quentin-Fallavier, France) and 0.3 µg/ml of PGI2 (Sigma-Aldrich, Saint Quentin-Fallavier, France).
The tested staphylococcal strains were the S. aureus ATCC43866 reference strain, 4 S. aureus clinical strains 
isolated from bacteremia patients (SaB) 19, 24, 31, 32 and the non-pathogenic food-derived S. condimenti (SC) 
strain. For each experiment, the bacterial strains were plated, from frozen cryobead stocks, on blood agar plates 
and incubated overnight at 37 °C. Then, after checking for the absence of contaminating colonies and variants, a 
Mueller-Hinton broth was seeded with a small number of colonies and cultured under agitation for 24 h at 37 °C. 
A Mueller-Hinton broth was then seeded with 2 ml of the 24 h-culture and incubated at 37 °C for 4 h to reach the 
exponential phase. Bacterial cells were washed, resuspended in Tyrode’s Buffer and adjusted to 1.2 × 108 CFU/ml.
Platelet exposure to Staphylococcus strains. Staphylococcal strains (50 µl, corresponding to 6 × 106 
CFU) or Tyrode’s Buffer (50 µl, as a non-stimulated (NS) control) were added to freshly prepared platelets (200 µl, 
corresponding to 6 × 107 platelets) in a 96-well uncoated polystyrene culture microplate to obtain a multiplicity 
of infection (MOI) of 0.1 (i.e., 1 bacteria for 10 platelets). Next, 50 µl of either ASA (500 µM final concentration, 
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Sigma-Aldrich, Saint Quentin-Fallavier, France), fluvastatin (10 µM final concentration, Sigma-Aldrich, Saint 
Quentin-Fallavier, France) or control vehicle (water, the resolubilization liquid for both ASA and fluvastatin) 
were added to the suspension. The concentrations of ASA and fluvastatin used in vitro to antagonize the effects 
of staphylococcal stimulation were determined by stimulating the platelets with the ATCC43866 reference strain 
in the presence of increasing concentrations of antiplatelet molecules, ranging from 0 to 5000 µM for ASA and 
100 µM for fluvastatin, based on previous studies72, 83. The lowest concentration of antiplatelet molecule that 
inhibited RANTES release by platelets was chosen for further experiments (i.e., 500 µM final concentration, 
Supplemental Fig. 5). However, 10 µM fluvastatin failed to inhibit RANTES release by platelets and was therefore 
used as a control for further experiments. The culture plate containing the platelet and bacterial mix was then 
gently centrifuged for 5 min at 300 × g to facilitate and standardize contact between platelets and bacteria. The 
plate was then incubated, without stirring, for 30 min at room temperature. As positive controls for either activa-
tion or platelet cell death, platelets were also stimulated for 30 min at room temperature with 50 µg/ml thrombin 
receptor activator peptide (TRAP-SFLLRN, Sigma-Aldrich, Saint Quentin-Fallavier, France) or with the apopto-
sis inducer A23187 (Merck Millipore, Guyancourt, France), respectively.
After stimulation, platelets were resuspended by gentle pipetting, and an aliquot of the suspension was col-
lected for viable normal platelet count and flow cytometry analysis. The plate was then re-centrifuged at 300 × g 
for 10 min to harvest the platelets, and the supernatants were collected and kept frozen at −80 °C until analysis.
Assessment of platelet mitochondrial membrane potential (ΔΨm). To determine whether plate-
let exposure to staphylococcal strains induced platelet cell death, the mitochondrial membrane potential (ΔΨm) 
was assessed in platelets. After bacterial stimulation, 40 nM DiOC6(3), a cell-penetrable green fluorescent cat-
ionic dye (Invitrogen, Saint Aubin, France), was added to the cell suspension for 15 min at room temperature. 
The samples were then diluted in phosphate-buffered saline (PBS) prior to flow cytometry analysis on a CANTO 
II flow cytometer with BD FACSDiva™ software (BD Biosciences, Le pont de Claix, France). Depolarization of 
the mitochondria was defined as a decrease in the mean fluorescence intensity of platelet-bound DIOC6(3), as 
observed in the FL1 channel.
Assessment of platelet phosphatidylserine externalization. Phosphatidylserine exposed on the 
membrane of apoptotic or necrotic cells was quantified by flow cytometry. In brief, after stimulation, platelets 
were resuspended in Annexin Binding Buffer (MabTag, Oldenburg, Germany) for immunostaining. PS exposure 
was determined after gating on CD41-positive cells (CD41 is a specific marker for platelets). Allophycocyanin 
(APC)-conjugated anti-human Annexin V (clone), fluorescein isothiocyanate (FITC) anti-human CD41 (clone 
HIP-8) and fluorochrome-conjugated mouse IgG isotypic controls were purchased from BD Biosciences (Le 
pont de Claix, France). All analyses were performed with a CANTO II flow cytometer and analyzed with BD 
FACSDiva™ software (BD Biosciences).
Platelet microparticle preparation and flow cytometry analysis. After stimulation, PRP was cen-
trifuged at 1,100 × g for 15 min to obtain platelet-poor plasma (PPP) containing PMPs. Then, PPP was centri-
fuged at 7,000 × g for 3 min. Supernatants were collected and kept frozen at −80 °C until flow cytometry analysis. 
PMPs were measured using Gallios flow cytometry as previously described by Robert et al.84. Briefly, PMPs were 
defined as CD41 and Annexin V positive, gating with Megamix beads (Biocytex, Marseille, France). PMPs were 
labeled following a 30-min incubation of PPP with APC-conjugated anti-human (MabTag, Oldenburg, Germany) 
and FITC anti-human CD41 (BD Biosciences) or fluorochrome-conjugated mouse IgG isotypic controls. During 
immunostaining, Annexin binding buffer was added to improve the binding of Annexin–V to PS. PMPs were 
fixed by addition of paraformaldehyde (4%); Cytocount beads (Dako/Agilent, Les Ulis, France) were used to 
determine the concentration. All analyses were performed using Kaluza® flow analysis software.
Assessment of caspase-3 activation. Stimulated platelets were resuspended in BD Cytofix/Cytoperm™ 
solution (BD Biosciences, Le pont de Claix – France) and incubated for 20 min on ice according to the manu-
facturer’s instructions. Platelets were then centrifuged 300 × g for 5 min, and the pellet was washed twice with 
BD Perm/Wash™ buffer. Platelets were resuspended in Perm/Wash™ buffer, stained with 20 µl of FITC rabbit 
anti-active Caspase-3 antibody (BD Biosciences) for 30 min at room temperature, washed once and analyzed with 
a CANTO II flow cytometer and BD FACSDiva™ software (BD Biosciences).
Assessment of cytokine release by platelets. The release of sCD62P, RANTES, GROα and sCD40L by 
platelets was measured in duplicate in the supernatants of unstimulated (negative control) or TRAP-stimulated 
(positive control) platelets and in the supernatants of platelets exposed to staphylococcal strains in the pres-
ence or absence of ASA (500 µM) or fluvastatin (10 µM). RANTES and Thromboxane B2 were quantified by 
ELISA (R&D Systems Europe Ltd., Lille, France). The absorbance at 450 nm was measured on an ELISA reader 
(Magellan software, Sunrise™, Tecan Group Ltd., Lyon, France). Soluble CD40L, sCD62P and GROα were quan-
tified using a multiplexed Luminex® system (Merck Millipore, Guyancourt, France) according to the manufac-
turer’s instructions. The results were read using a Bioplex 200 system (Bioplex Manager™ software, Bio-Rad, 
Marnes-la-Coquette, France).
Assessment of platelet aggregation. Platelet aggregation was assessed throughout the platelet stim-
ulation (30 min) with the staphylococcal strains described above using a Thrombo-aggregometer TA 4 V with 
constant stirring and was analyzed with Thrombosoft 1.6 software (SD Innovation, Frouard, France). At the end 
of the platelet stimulation, TRAP (50 µg/ml) or ADP (10 µM) was added to the PRP suspension to confirm that 
the platelets were still responsive to stimulation. Calibration of the thrombo-aggregometer utilized PRP (0% light 
transmission, 0% aggregation) and PPP (100% light transmission, 100% aggregation), which was obtained by 
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centrifuging the unstimulated PRP at 3000 × g for 20 min. The data for the PRP samples that revealed an aggre-
gation, even partial, was not included in the whole aggregation dataset and were presented individually, as shown 
in Supplemental Fig. 3.
Analysis of platelet activation markers. Platelet membrane expression of the CD62P and CD63 acti-
vation markers after stimulation was assessed using immunostaining of PRP after gating on CD41-positive cells 
(CD41 is a specific marker for platelets). APC-conjugated anti-human CD41 (clone HIP-8), FITC anti-human 
CD62P (clone AK-4), phycoerythrin (PE) CD63 (clone HSC-6) and fluorochrome-conjugated mouse IgG iso-
typic controls were purchased from BD Biosciences (Le pont de Claix, France). All analyses were performed with 
a CANTO II flow cytometer and analyzed with BD FACSDiva™ software (BD Biosciences).
Platelets and S. aureus fluorescence microscopy. The staphylococcal strain SAB24 express-
ing eGFP, obtained by transforming the SAB24 strain with the pbSU101 plasmid (a kind gift from Prof. 
Spellerberg, University of Ulm, Germany) as previously described85, 86, TRAP (as a positive control) or 
Tyrode’s Buffer (as a non-stimulated (NS) control) were added to freshly prepared platelets as described in 
the “Platelet exposure to Staphylococcus strains” paragraph and placed in a μClear® polystyrene microplate 
with a bottom thickness of 190 μm +/− 20 μm (Greiner Bio-One, Courtaboeuf, France). The culture plate 
containing the platelet and bacterial mix was then gently centrifuged for 5 min at 300 × g to facilitate and 
standardize contact between platelets and bacteria and was incubated for 30 min at room temperature. The 
platelets were then fixed with 4% paraformaldehyde, washed twice with PBS and stained with an anti-human 
CD41 Dylight 550 antibody (Leinco Technologies®/Interchim, Montluçon, France; 10 µg/ml). Finally, 
the platelets were washed once with PBS and observed with an IX81 fluorescence inverted microscope 
(Olympus, Germany) using Cell^P software (Olympus, Germany). The total number of platelets and the 
number of platelets with a normal size (less than 4 μm) was determined in each field, and the percentage of 
normal-sized platelets was calculated.
Measurement of endotoxin levels in PRP. The absence of any contaminating bacterial endotoxin in 
PRP was confirmed by inoculation of 1 ml of PRP into conventional blood culture medium, incubation in a BD 
Bactec™ automated system (Becton Dickinson) and analysis using the QCL-1000 Limulus amoebocyte lysate 
assay® (Lonza/Ozyme, Montigny-Le-Bretonneux, France).
Statistical analysis. One or two-way ANOVA with repeated measures and a Bonferroni post hoc test were 
used for inter-experimental comparisons. All values are reported as the mean ± standard error of the mean 
(SEM). A p-value of <0.05 was considered statistically significant. Dixon tests were used to identify abnormal 
values. Statistical analyses and graphs were performed with GraphPad Prism 5 (La Jolla, USA) and FlowJo V10 
(Ashland, USA) software.
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